Infections due to respiratory syncytial virus (RSV) have seriously troubled drug makers for decades and the need for a vaccine was on since the 1960s. According to the assessment done by DelveInsight on the latest published “Respiratory Syncytial Virus Epidemiology Report,” it is estimated to affect approximately 5 million cases this year in the United States and 2.5 million cases in the EU4 countries and the United Kingdom. As per the analysis, the highest RSV incident cases were comprised of mild cases (~70%), in children, whereas, in adults, the highest RSV incident cases were found to be moderate (~64%), in 2022 in the US.
Despite many clinically failed attempt...
